<DOC>
	<DOCNO>NCT00802555</DOCNO>
	<brief_summary>Multi-center , single-arm Phase 1b study design evaluate safety tolerability ARQ 197 cirrhotic patient HCC .</brief_summary>
	<brief_title>Safety Study ARQ 197 Cirrhotic Patients With Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Study design evaluate safety tolerability ARQ 197 cirrhotic patient HCC receive ≤2 prior systemic regimen HCC , whose liver disease severity categorize Class A B per Child-Pugh Classification .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Written inform consent grant prior initiation studyspecific screening procedure , give understanding patient right withdraw study time , without prejudice 18 year age old Histologically cytologically confirm HCC ( require : hepatic lesion &gt; 2cm diameter , suggestive HCC radiology αfetoprotein ( AFP ) &gt; 200 mg/mL ) Barcelona Clinic Liver Cancer ( BCLC ) stag Category27 A , B C benefit treatment establish efficacy and/or high priority Cirrhotic status ChildPugh Class A B without ascites slight ascites recognize image technique and/or manage easily diuretic ( e.g . 100 mg spironolactone per day and/or furosemide 40 mg/day ) Cirrhotic status confirm one follow methods/evidence : Biopsy Endoscopy show gastrointestinal tract varix Evidence portal hypertension image study dilate portal vein , collateral circulation ECOG PS ≤1 Not two prior systemic regimen HCC last treatment must complete ≥4 week prior first dose ARQ 197 Local locoregional therapy ( i.e. , surgery , radiation therapy , hepatic arterial embolization , chemoembolization , radiofrequency ablation , percutaneous ethanol injection , cryoablation ) must complete ≥4 week prior first dose ARQ 197 Measurable disease define revise Response Evaluation Criteria Solid Tumors ( RECIST ) , version 1.1 . Tumor lesion select target lesion ( ) baseline previously treat local therapy ( naïve tumor lesion ) Adequate bone marrow , liver , renal function , define : Platelet count ≥ 60 × 10^9/L Hemoglobin ≥ 8.5 g/dL Absolute neutrophil count ( ANC ) ≥1.5 × 10^9/L Total bilirubin ≤ 3 mg/dL Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤ 5 × upper limit normal ( ULN ) Serum creatinine ≤1.5 × ULN International normalize ratio ( INR ) ≤ 2.3 PT ≤ 6.0 second control . Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality exist parameter Albumin ≥ 2.8 g/dL Women childbearing potential must negative pregnancy test perform within seven day prior start study drug Male female subject childbearing potential must agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study 90 day last investigational drug dose receive Previous concurrent cancer distinct HCC primary site histology , EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat &gt; 3 year prior enrollment permit History cardiac disease : congestive heart failure define Class II IV per New York Heart Association ( NYHA ) classification ; active coronary artery disease ( CAD ) ; previously diagnose bradycardia cardiac arrhythmia , uncontrolled hypertension ; myocardial infarction occur within 6 month prior study entry ( myocardial infarction occur &gt; 6 month prior study entry permit ) Active clinically serious infection define ≥ Grade 2 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , version 3.0 Substance abuse , medical , psychological social condition may , opinion Investigator , interfere patient 's participation study evaluation study result Any condition unstable could jeopardize safety patient his/her protocol compliance Known HIV ( human immunodeficiency virus ) infection Pregnancy breastfeed History liver transplant Inability swallow oral medication Clinically significant gastrointestinal bleeding occur ≤4 week prior first dose ARQ 197</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HCC</keyword>
	<keyword>Cirrhotic Patients Hepatocellular Carcinoma</keyword>
</DOC>